Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NG2 and DLL3 CAR-T Therapy Targeting Melanoma
NCT07193966Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NG2 CAR-T cells + DLL3 CAR-T cells in melanoma, sponsored by Shenzhen Geno-Immune Medical Institute. Started Sep 2025; status: terminated.
02
Drugs
NG2 CAR-T cells + DLL3 CAR-T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07193966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193966.